Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 686-691, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-772379
ABSTRACT
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Receptor Protein-Tyrosine Kinases
/
Carcinoma, Non-Small-Cell Lung
/
Diagnosis
/
ErbB Receptors
/
Anaplastic Lymphoma Kinase
/
Genetics
/
Lung Neoplasms
/
Mutation
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS